# US 2020/0347436 A1 · Tie2 receptor activation for glaucoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347436 A1
- Document ID: US20200347436A1
- Status: Published application
- Kind: A1
- Application number: 16/711,067
- Filed: 2019-12-11
- Published: 2020-11-05
- Earliest claimed: 2014-07-03
- Assignees: Mannin Research Inc.
- Applicants: Mannin Research Inc.
- Inventors: Susan E. QUAGGIN
- Web page: https://patentgrep.com/patent/US20200347436A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 27/02: Ophthalmic agents
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A01K 67/0276: Knock-out vertebrates
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- C07K 14/515: Angiogenesic factors; Angiogenin
- C12Q 1/686: Polymerase chain reaction [PCR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention relates to the production and genotyping of mice lacking both Angiopoietin 1 and Angiopoietin 2. This invention also relates to the use of Tie2 receptor activation for treatment of open angle glaucoma, congenital glaucoma and cystic kidney disease, and more specifically to the use of angiopoietin 1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and Tie2-peptomimetics to improve lymphatic drainage in the Schlemm's canal and corneal limbal lymphatic system for open angle glaucoma and congenital glaucoma patients, and to slow and/or reduce the growth of cysts in patients with cystic kidney disease.

## Claims

### Claim 1

A method of treating a patient having open angle glaucoma, congenital glaucoma or cystic kidney disease, or for improving ocular lymphatic drainage in the patient comprising administering to the patient a pharmaceutical composition comprising one or more agents capable of TIE2 receptor activation, one or more of angiopoietin-1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and/or Tie2-peptidomimetics.

### Claim at position 2

-7. (canceled)

### Claim 8

A conditional Angiopoeitin 2 knockout allele.

### Claim at position 4

-10. (canceled)

### Claim 11

A method for treatment of cystic kidney disease in a subject in need thereof, comprising administering to the subject an effective dosage amount of a pharmaceutical composition comprising one or more Tie2 receptor activating agents.

### Claim 12

(canceled)
